Psoriatic Arthritis (PsA) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease associated with joints and the place where tendons and ligaments are connected to bone and usually occurs in combination with a skin disorder called psoriasis. Enthesitis is one of the most common characteristic features. Other clinical features, including swelling joints, itchy-painful red patches, silvery while building up dead skin cells, and PsA also affect the sacroiliac joint of the pelvic and spine, causing stiffness in and around the neck and back. The exact cause of psoriatic arthritis is still unknown. It starts emerging in individuals aged 30 to 50 and can begin as early as childhood. Both genders are equally at the same risk level. The genetic epidemiology of PsA also supports its unique status. PsA has been associated with human leukocyte antigen (HLA) class 1 alleles as opposed to the type 2 alleles associated with RA. Extra-articular manifestations of PsA are also different from those of RA. In particular, rheumatoid nodules are absent. Rheumatoid factor, detected in more than 80% of patients with RA, may be seen in about 13% of patients with PsA.

 

The prevalence of Psoriatic arthritis (PsA) ranges from 0.05% to 0.25% in the general population and 6% to 41% in psoriasis patients.

 

The competitive landscape of Psoriatic Arthritis (PsA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Psoriatic Arthritis (PsA) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Psoriatic Arthritis (PsA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake, and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Psoriatic Arthritis (PsA) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          SUNPG18_07   Sun Pharmaceutical Industries Limited   Phase 3

2          Secukinumab    Novartis Pharmaceuticals          Phase 3

3          Apremilast        Amgen  Phase 3

4          Bimekizumab    UCB Biopharma SRL     Phase 3

5          Tofacitinib         Pfizer    Phase 3

6          Brodalumab      Bausch Health Americas, Inc.    Phase 3

7          Guselkumab     Janssen Research & Development, LLC Phase 3

8          BMS-945429     CSL Behring     Phase 2

9          Ixekizumab       Eli Lilly and Company    Phase 3

10        Risankizumab   AbbVie  Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more